Memo Therapeutics Company

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Technology: Precision Medicine
Industry: P3 Medicine
Headquarters: Zürich, Zurich, Switzerland
Founded Date: 2012
Employees Number: 1-10
Funding Status: Early Stage Venture

Visit Website
Register and Claim Ownership